Expression of Metallothionein in Oral Cancer

Dzięgiel, Piotr; Puła, Bartosz; Podhorska-Okołów, Marzena

doi:10.5772/30549

Cited by 1 publication

(1 citation statement)

References 96 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The translocation of MT into the nucleus during G1/S phase in tumor cells suggests that MT facilitates cell proliferation by donating zinc ions to various transcription factors. 9,20,21,22 In this sense, it is of high importance to distinguish between MT-I+II expression both in subcellular compartments (e.g. cytoplasmic vs. nuclear).…”

Section: Discussionmentioning

confidence: 99%

Nuclear metallothionein in oral squamous cell carcinoma: clinicopathological parameters and patient survival

Bezerra¹,

Pontes²,

Neto³

et al. 2018

Braz. oral res.

View full text Add to dashboard Cite

The aim of this study was to identify the immunoexpression of methallothionein in oral squamous cell carcinoma as well as to address the correlation with clinical features, histological grade and patient survival. Samples were collected from 93 patients with tongue squamous cell carcinoma who presented for follow-up. Immunohistochemical expression of methallothionein in all groups was performed. The scoring system has previously been published by Tsurutani in 2005, which is based on intensity and distribution of staining. We used Kappa index to evaluate the degree of observers' agreement under metallothionein immunostaining and histological grade. Associations between methallothionein expression and clinical parameters (age, gender, smoking, tumor size, lymph node metastasis and disease stage) were examined for statistical significance using the chi-squared test. The overall survival rates were estimated by the Kaplan-Meier method and the relationship between protein expression and survival was compared using the log-rank test (p < 0.05). Our results showed no statistically significant association between methallothionein immunostaining and the selected clinicopathological variables. Immunohistochemistry results showed positive nuclear immunostaining for metallothionein in 62,37% (58/93) and negative for metallothionein 37,63% (35/93). The degree of examiners agreement by Kappa varied from substantial to perfect and both metallothionein immunostaining and histological grade were explored. The present study suggests that positive methallothionein expression found in tongue squamous cell carcinoma may not help to predict survival in the analyzed samples, as well as no relation between the protein and histological grade and clinical features was observed. In conclusion, the present study suggests that metallothionein is not associated with tongue squamous cell carcinoma clinicopathological characteristics and aggressiveness.

show abstract

Section: Discussionmentioning

confidence: 99%